Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma

Children's Oncology Group

Status: Completed

Conditions: Sarcoma

Treatments: Genetic: RNA analysis; Other: laboratory biomarker analysis; Genetic: gene expression analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01433237

NCI-2011-03457 (Registry Identifier)

COG-ARST12B1 (Other Identifier)

ARST12B1 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.

Full description

OBJECTIVES:

• Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).

OUTLINE: Archived serum samples are analyzed for miR-206 expression.

PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.

Enrollment: 40 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified